• Skip to primary navigation
  • Skip to main content

Yamo Pharmaceuticals

Cutting Edge Pharmaceutial Technologies

  • Technology
    • Yamo’s Treatment for Autism
    • About Autism
  • Information for Patients and Caregivers
    • Future Clinical Studies
    • Compassionate Use Policy
  • Company
    • Overview
    • Our Team
    • Scientific Advisory Board
  • News & Publications
  • Contact Us
    • General Inquiries
    • Participation in Future Clinical Studies

Dr. John Rothman

Chief Scientific Advisor

  • Dr. Rothman has 30+ years of experience in product development across many disciplines and markets
  • From 2005 to 2013, he was Executive Vice President of Science & Operations at Advaxis, where he was responsible for R&D, toxicology, regulatory, chemistry, data management, manufacturing and intellectual property
  • As Director of Clinical Research at Roche for various clinical sections, he oversaw numerous development programs that resulted in marketed drugs, including Interferon-α, Rocephin, Coactin, Rimadyl, Larotid, Dalmane, Rimantidine, Gantrisin, Versed, etc.
  • Dr. Rothman conducted the 1st clinical trial in AIDS and wrote the first biologics application submitted (and approved) by the FDA
  • Drug development responsibilities included: Interferon, Midazolam, Rocephin, Coactin, Bactrim, Gantrisin, Valium, Klonopin, Dalmane, Fansidar, Larotid, Piquindone and others
  • Dr. Rothman attended the Tulane University School of Medicine, where he studied Pharmacology in the laboratory of Dr. Louis Ignarro (Nobel Prize in Medicine, 1998) and conducted his graduate research at the New Orleans VA Hospital in the laboratory of Dr. Andrew Schally (Nobel Prize in Medicine, 1977)
  • Copyright © 2022 Yamo Pharmaceuticals
  • Terms and Conditions
  • Privacy Policy